Merck’s gefapixant decreases chronic cough frequency in Phase III trials
Gefapixant is an antagonist of P2X3 receptor, which is present on sensory nerve fibers in the airway lining. Credit: Robina Weermeijer on Unsplash.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more